Publicacions en què col·labora amb Sandra Hervas Stubbs (23)

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  2. Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy

    PLoS ONE, Vol. 7, Núm. 12

  3. The HIF-1α hypoxia response in tumor-infi ltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy

    Cancer Discovery, Vol. 2, Núm. 7, pp. 608-623

  4. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.

    Journal of translational medicine, Vol. 10, pp. 122

2011

  1. Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

    PLoS ONE, Vol. 6, Núm. 3

  2. Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes

    PLoS ONE, Vol. 6, Núm. 12

  3. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy

    International Journal of Cancer, Vol. 128, Núm. 1, pp. 105-118

  4. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

  5. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386

2010

  1. Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α

    European Journal of Immunology, Vol. 40, Núm. 11, pp. 3054-3063

  2. Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates

    Molecular Therapy, Vol. 18, Núm. 4, pp. 754-765

  3. Interferon producing killer dendritic cells (IKDC): A matter of controversy

    Inmunologia, Vol. 29, Núm. 1, pp. 50-55

  4. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 8, pp. 1223-1233

2009

  1. Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?

    Immunotherapy, Vol. 1, Núm. 5, pp. 845-853

  2. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

    European Journal of Immunology, Vol. 39, Núm. 9, pp. 2424-2436

  3. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

    British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119

2008

  1. Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells

    Gene Therapy, Vol. 15, Núm. 7, pp. 473-483

  2. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

    Clinical Cancer Research, Vol. 14, Núm. 21, pp. 6895-6906

2007

  1. Absence of surface expression of CD137 (4-1BB) on Myeloid-derived suppressor cells

    Inmunologia, Vol. 26, Núm. 3, pp. 121-126

  2. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

    Expert Opinion on Biological Therapy, Vol. 7, Núm. 5, pp. 599-615